Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases.
Identifieur interne : 000106 ( Main/Corpus ); précédent : 000105; suivant : 000107Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases.
Auteurs : Zeyad A. Alzahrani ; Khalid Abdullah Alghamdi ; Ahmed Saeed AlmaqatiSource :
- Rheumatology international [ 1437-160X ] ; 2021.
English descriptors
- KwdEn :
- MESH :
- diagnosis : Rheumatic Diseases.
- drug therapy : Rheumatic Diseases.
- epidemiology : Rheumatic Diseases.
- Adult, Aged, COVID-19, Cohort Studies, Female, Humans, Male, Retrospective Studies, SARS-CoV-2.
Abstract
This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases and identify the risk factors associated with severe COVID-19 pneumonia. This was a retrospective study in a tertiary care center conducted through the period between March 2020 and November 2020 and included all adult patients with rheumatic diseases who tested positive on the COVID-19 polymerase chain reaction (PCR) test. We assessed the patients' demographic data, history of rheumatic disease, COVID-19 symptoms and experimental treatment, if any, their disease course, and outcome. In all, 47 patients were included, and most were females. The commonest rheumatic diseases were rheumatoid arthritis (53.2%), followed by systemic lupus erythematosus (21.3%), and psoriatic arthritis (10.6%). Methotrexate and hydroxychloroquine were the most commonly used disease-modifying anti-rheumatic drugs in 36.1% and 25.5%, respectively. Out of 47 patients, 48.9% required hospitalization with a median hospital stay of 7 days. Severe COVID-19 pneumonia, defined as clinical signs of pneumonia plus one of the following: respiratory rate > 30 bpm, severe respiratory distress, or oxygen saturation < 90% in room air was observed in 19.1% of the patients, and one patient died. We found that elderly patients with a mean age of 65.3 years were more likely to develop severe COVID-19 pneumonia and that was statistically significant. Our study showed that elderly patients with a mean age of 65 years and having rheumatic diseases had an increased risk of hospital admission and development of severe COVID-19 pneumonia.
DOI: 10.1007/s00296-021-04857-9
PubMed: 33856543
PubMed Central: PMC8046898
Links to Exploration step
pubmed:33856543Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases.</title><author><name sortKey="Alzahrani, Zeyad A" sort="Alzahrani, Zeyad A" uniqKey="Alzahrani Z" first="Zeyad A" last="Alzahrani">Zeyad A. Alzahrani</name><affiliation><nlm:affiliation>Medicine/Rheumatology, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Rheumatology, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Alghamdi, Khalid Abdullah" sort="Alghamdi, Khalid Abdullah" uniqKey="Alghamdi K" first="Khalid Abdullah" last="Alghamdi">Khalid Abdullah Alghamdi</name><affiliation><nlm:affiliation>Department of Rheumatology, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Almaqati, Ahmed Saeed" sort="Almaqati, Ahmed Saeed" uniqKey="Almaqati A" first="Ahmed Saeed" last="Almaqati">Ahmed Saeed Almaqati</name><affiliation><nlm:affiliation>Department of Internal Medicine, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia. almaqatias@gmail.com.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>King Abdullah International Medical Research Center, Jeddah, Saudi Arabia. almaqatias@gmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33856543</idno><idno type="pmid">33856543</idno><idno type="doi">10.1007/s00296-021-04857-9</idno><idno type="pmc">PMC8046898</idno><idno type="wicri:Area/Main/Corpus">000106</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000106</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases.</title><author><name sortKey="Alzahrani, Zeyad A" sort="Alzahrani, Zeyad A" uniqKey="Alzahrani Z" first="Zeyad A" last="Alzahrani">Zeyad A. Alzahrani</name><affiliation><nlm:affiliation>Medicine/Rheumatology, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Rheumatology, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Alghamdi, Khalid Abdullah" sort="Alghamdi, Khalid Abdullah" uniqKey="Alghamdi K" first="Khalid Abdullah" last="Alghamdi">Khalid Abdullah Alghamdi</name><affiliation><nlm:affiliation>Department of Rheumatology, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Almaqati, Ahmed Saeed" sort="Almaqati, Ahmed Saeed" uniqKey="Almaqati A" first="Ahmed Saeed" last="Almaqati">Ahmed Saeed Almaqati</name><affiliation><nlm:affiliation>Department of Internal Medicine, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia. almaqatias@gmail.com.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>King Abdullah International Medical Research Center, Jeddah, Saudi Arabia. almaqatias@gmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Rheumatology international</title><idno type="eISSN">1437-160X</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>COVID-19 (MeSH)</term><term>Cohort Studies (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>Rheumatic Diseases (diagnosis)</term><term>Rheumatic Diseases (drug therapy)</term><term>Rheumatic Diseases (epidemiology)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>COVID-19</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Retrospective Studies</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases and identify the risk factors associated with severe COVID-19 pneumonia. This was a retrospective study in a tertiary care center conducted through the period between March 2020 and November 2020 and included all adult patients with rheumatic diseases who tested positive on the COVID-19 polymerase chain reaction (PCR) test. We assessed the patients' demographic data, history of rheumatic disease, COVID-19 symptoms and experimental treatment, if any, their disease course, and outcome. In all, 47 patients were included, and most were females. The commonest rheumatic diseases were rheumatoid arthritis (53.2%), followed by systemic lupus erythematosus (21.3%), and psoriatic arthritis (10.6%). Methotrexate and hydroxychloroquine were the most commonly used disease-modifying anti-rheumatic drugs in 36.1% and 25.5%, respectively. Out of 47 patients, 48.9% required hospitalization with a median hospital stay of 7 days. Severe COVID-19 pneumonia, defined as clinical signs of pneumonia plus one of the following: respiratory rate > 30 bpm, severe respiratory distress, or oxygen saturation < 90% in room air was observed in 19.1% of the patients, and one patient died. We found that elderly patients with a mean age of 65.3 years were more likely to develop severe COVID-19 pneumonia and that was statistically significant. Our study showed that elderly patients with a mean age of 65 years and having rheumatic diseases had an increased risk of hospital admission and development of severe COVID-19 pneumonia.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33856543</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>06</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases.</ArticleTitle><Pagination><MedlinePgn>1097-1103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-021-04857-9</ELocationID><Abstract><AbstractText>This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases and identify the risk factors associated with severe COVID-19 pneumonia. This was a retrospective study in a tertiary care center conducted through the period between March 2020 and November 2020 and included all adult patients with rheumatic diseases who tested positive on the COVID-19 polymerase chain reaction (PCR) test. We assessed the patients' demographic data, history of rheumatic disease, COVID-19 symptoms and experimental treatment, if any, their disease course, and outcome. In all, 47 patients were included, and most were females. The commonest rheumatic diseases were rheumatoid arthritis (53.2%), followed by systemic lupus erythematosus (21.3%), and psoriatic arthritis (10.6%). Methotrexate and hydroxychloroquine were the most commonly used disease-modifying anti-rheumatic drugs in 36.1% and 25.5%, respectively. Out of 47 patients, 48.9% required hospitalization with a median hospital stay of 7 days. Severe COVID-19 pneumonia, defined as clinical signs of pneumonia plus one of the following: respiratory rate > 30 bpm, severe respiratory distress, or oxygen saturation < 90% in room air was observed in 19.1% of the patients, and one patient died. We found that elderly patients with a mean age of 65.3 years were more likely to develop severe COVID-19 pneumonia and that was statistically significant. Our study showed that elderly patients with a mean age of 65 years and having rheumatic diseases had an increased risk of hospital admission and development of severe COVID-19 pneumonia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alzahrani</LastName><ForeName>Zeyad A</ForeName><Initials>ZA</Initials><Identifier Source="ORCID">0000-0001-8696-7930</Identifier><AffiliationInfo><Affiliation>Medicine/Rheumatology, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghamdi</LastName><ForeName>Khalid Abdullah</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-3064-7097</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almaqati</LastName><ForeName>Ahmed Saeed</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-0557-0219</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia. almaqatias@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Abdullah International Medical Research Center, Jeddah, Saudi Arabia. almaqatias@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Ann Rheum Dis. 2020 Dec;79(12):1544-1549</RefSource><PMID Version="1">32796045</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antirheumatic drugs</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Rheumatic diseases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33856543</ArticleId><ArticleId IdType="doi">10.1007/s00296-021-04857-9</ArticleId><ArticleId IdType="pii">10.1007/s00296-021-04857-9</ArticleId><ArticleId IdType="pmc">PMC8046898</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395(10223):497–506</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Map—Johns Hopkins Coronavirus Resource Center 2021. https://coronavirus.jhu.edu/map.html . Accessed 28 Jan 2021</Citation></Reference><Reference><Citation>World Health Organization (2020) Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization. https://apps.who.int/iris/handle/10665/332196 . Accessed 28 Jan 2021</Citation></Reference><Reference><Citation>Wang L, He W, Yu X, Hu D, Bao M, Liu H et al (2020) Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 80(6):639–645</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R et al (2020) Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 79(12):1544–1549</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218296</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P et al (2020) Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med 383(1):85–88</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2009567</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859–866</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W et al (2020) Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 369:m1849</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1849</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Landray MJ (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384(8):693–704. https://doi.org/10.1056/NEJMoa2021436</Citation></Reference><Reference><Citation>Malgie J, Schoones JW, Pijls BG (2020) Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis Sep 23:ciaa1445. https://doi.org/10.1093/cid/ciaa1445</Citation></Reference><Reference><Citation>Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F et al (2021) Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis Rheumatol 73(1):36–47</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41469</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2021) Men, ageing and health: achieving health across the life span. World Health Organization, Geneva. Accessed 27 Jan 2021</Citation></Reference><Reference><Citation>FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors (2020) Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 80(4):527–538. (annrheumdis-2020-218310)</Citation></Reference><Reference><Citation>Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis (2021:annrheumdis-2020-219498)</Citation></Reference><Reference><Citation>Hasseli R, Mueller-Ladner U, Schmeiser T, Hoyer BF, Krause A, Lorenz HM et al (2020) National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open 6(2):e001332. https://doi.org/10.1136/rmdopen-2020-001332</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001332</ArticleId><ArticleId IdType="pubmed">32878994</ArticleId><ArticleId IdType="pmcid">7507994</ArticleId></ArticleIdList></Reference><Reference><Citation>Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J et al (2020) Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int 40(10):1593–1598</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04676-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Patanavanich R, Glantz SA (2020) Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res 22(9):1653–1656</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ntr/ntaa082</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L et al (2020) COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2(9):e557–e564</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30227-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A et al (2020) Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(11):1393–1399</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217984</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM et al (2020) Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US “hot spot.” Ann Rheum Dis 79(9):1156–1162</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217888</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Gutierrez B, Leon L, Madrid A, Rodriguez-Rodriguez L, Freites D, Font J et al (2021) Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. Ther Adv Musculoskelet Dis 13:1759720X20962692</Citation></Reference><Reference><Citation>Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F, Brescia Rheumatology C-SG (2020) COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol 2(9):e549–e56</Citation></Reference><Reference><Citation>Ahmed S, Gasparyan AY, Zimba O (2021) Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 41(2):243–256. https://doi.org/10.1007/s00296-020-04764-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04764-5</ArticleId><ArticleId IdType="pubmed">33388969</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos CS, Férnandez XC, Moriano Morales C, Álvarez ED, Álvarez Castro C, López Robles A et al (2021) Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe? RMD Open 7(1):e001439</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001439</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos CS, Morales CM, Álvarez ED, Castro CÁ, Robles AL, Sandoval TP (2020) Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol 39(9):2789–2796</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05301-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha AP, Atallah ÁN, Pinto ACPN, Rocha-Filho CR, Milby KM, Civile VT et al (2020) COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review. Sao Paulo Med J 138:515–520</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1516-3180.2020.0421.r2.10092020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA et al (2020) Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis 79(7):988–990</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217948</ArticleId></ArticleIdList></Reference><Reference><Citation>Loarce-Martos J, García-Fernández A, López-Gutiérrez F, García-García V, Calvo-Sanz L, Del Bosque-Granero I et al (2020) High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int 40(12):2015–2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04699-x</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000106 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000106 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33856543
|texte= Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33856543" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |